Support
Contact us
English
Back to lobby 
Gil Ben-Horin Published: Nov 16, 2016
A prospective observational study at Centre Hospitalier Universitaire Vaudois (CHUV) evaluated OMNI®, a new device for continuous renal replacement therapy (CRRT), by testing it in real-life conditions for the first time. The authors also assessed user (nurses) satisfaction and aimed to provide direct feedback to the manufacturer regarding issues raised and user interface improvement suggestions. Ten critically ill patients received CRRT in CVVH-heparin and CVVHD-citrate modes using OMNI. The authors collected therapy data and metabolic parameters using MetaVision, and evaluated user’s satisfaction with a survey. The authors found that, “RRT could be provided using Omni in a safe and efficient way in both CVVH-heparin and CVVHD-RCA modes in 10 critically ill patients. Alarms-related downtime was minimal and renal dose delivery high. Users provided positive feedback for therapy setup, management and design.”
Gil Ben-Horin Jacob Krygier is a Clinical Application Specialist at iMDsoft with 20 years of hands-on healthcare experience. His background spans operating rooms, intensive care units, emergency medicine, and medivac air ambulances, with specialized expertise in anesthesia and emergency care.
Book a demo 
Login to Support Portal 
